Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been making waves in the healthcare sector with its groundbreaking treatments for diabetes and obesity.
Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here’s why
Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 million below the low end of the company’s prior guidance and includes $3.5 billion from its type 2 diabetes drug Mounjaro and $1.
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels. Eli Lilly now expects revenue to be approximately $13.
Eli Lilly Stock's Correction Brings Opportunity
Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.
Eli Lilly's SWOT analysis: stock poised for growth amid challenges
Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a landscape of robust demand for its groundbreaking diabetes and obesity treatments,
Should You Buy the Dip in Eli Lilly Stock Right Now?
All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly dropped by as much as 8% and ended the day down around 6%. Year-to-date, share prices are down about 1.4%.
Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Eli Lilly: Market Overreacted
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Yahoo Finance15d
LLY Stock Down on Lower-Than-Expected Sales Guidance for Q4
Lilly is scheduled to report its fourth-quarter and full-year 2024 results on Feb. 6. Lilly’s stock has risen 17.5% in the past year against a decrease of 1.4% for the industry. Lilly ...
Business Insider1d
Eli Lilly Stock , LLY
Earnings Report 5.212 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 4.918 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.695 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...
AOL16d
Eli Lilly stock tumbles after new forecasts show weight-loss drug sales grow slower than expected
and U.S. supply across all doses of tirzepatide was available throughout Q4," said Lilly CEO David Ricks in a statement. The move in the stock surprised some experts and analysts since the ...
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
Business Insider16d
Eli Lilly & Co: Strong Long-Term Growth Prospects Amid Q4 Revenue Shortfall Justify Buy Rating
Despite the Q4 miss, these factors suggest that Eli Lilly holds a promising growth profile ... Citi also maintained a Buy rating on the stock with a $1,250.00 price target. TipRanks tracks over ...
AOL7d
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
Results for the fourth quarter of 2024 should show revenue ... The problem, however, goes back to valuation. Eli Lilly is a stock which you might consider to be "priced to perfection" because ...